Urodynamic and Quality-of-Life Outcomes After Endometrial Cancer Treatment: A Prospective Cohort Study

Endometrial cancer therapy may affect lower urinary tract function and quality of life (QoL). We prospectively evaluated short-term urodynamic and QoL outcomes after surgical treatment with or without adjuvant radiotherapy.

Women with biopsy-confirmed endometrial cancer underwent standardized urodynamic testing before surgery and 6 months after treatment completion. Parameters included detrusor pressure, bladder capacity, compliance, and post-void residual (PVR) urine volume. QoL was assessed using EORTC QLQ-C30 and QLQ-EN24 questionnaires. Pre- and post-treatment data were compared using nonparametric tests (α = 0.05). Surgery was performed either robotically or via the open abdominal approach.

Of the 101 participants, 55 received adjuvant radiotherapy and 46 were treated with surgery alone. No clinically significant  urodynamic deterioration was observed post-surgery. Median PVR urine volume decreased from 50 to 40 mL (p = 0.002) and detrusor pressure from 30 to 28 cmH₂O (p = 0.08) following surgery; other parameters remained stable. No acute radiation cystitis occurred. QoL scores were high at baseline and follow-up, with no domain showing a ≥ 10-point change. Sexual and urinary symptom scores remained unchanged.

Within 6 months after endometrial cancer treatment, urodynamic parameters and QoL remained stable. These results suggest short-term functional safety of contemporary surgical and radiotherapy protocols, warranting longer-term follow-up.